ESMO 2023: Highlights on pembro + CRT in high-risk locally advanced cervical cancer: The KEYNOTE-A18 study
Share.
About Author
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
Related Posts
-
FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 stage III-IVA cervical cancer
-
ESMO 2023: Immunotherapy added to first-line standard therapy significantly improves survival in metastatic or recurrent cervical cancer
-
ESMO 2023: Cabozantinib dramatically improved progression-free survival in advanced neuroendocrine tumours